Market revenue in 2022 | USD 85.0 million |
Market revenue in 2030 | USD 242.4 million |
Growth rate | 14% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52% in 2022. Horizon Databook has segmented the India non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
In India, NIPT is allowed to be utilized only to detect genetic disorders in embryos, such as sickle cell anemia, cystic fibrosis, phenylketonuria, and thalassemia. NIPT procedures are carried out only at registered genetic clinics and by a registered & qualified person under the Pre-Conception and Prenatal Diagnostic Due to the high prices of NIPT, doctors sent the samples abroad for examination.
This was happening owing to the lack of labs in the country, but now some labs in India have initiated examination of NIPT tests within the country. Improvements in healthcare facilities in the country are likely to drive the market over the forecast period.
In March 2021, Bio serve Biotechnology launched NIPT services in the country. Under the PRENITA brand, the company provides diagnostic testing for prenatal and postnatal patients, advanced preimplantation genetic screening/diagnosis, and carrier screening services.
Horizon Databook provides a detailed overview of country-level data and insights on the India non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into India non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account